Anavex promotes a vice president regulatory affairs

Kristina M. Capiak, CCRP has been promoted the Anavex Life Sciences Corp’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.

Prior to joining Anavex, a clinical-stage developer of drugs to treat Alzheimer’s disease, Capiak was the Global Regulatory Lead at Retrophin, Inc. where she implemented U.S. and EU strategy for the ongoing development programs, which received orphan drug designations as well as fast track designation.

“We are excited to expand Ms. Capiak’s role to oversee the Company’s clinical development programs and other indications given Ms. Capiak’s expertise and we are delighted to have her on our team,” said Dr. Christopher U. Missling, PhD, President and Chief Executive Officer for Anavex.